Hepatitis B virus transgenic mice: Insights into the virus and the disease

Hepatology

Volumn 22, Issue 4 PART 1, 1995, Pages 1316-1325

  Chisari, Francis V ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; DNA SUPERCOILING; HEPATITIS; HEPATITIS B VIRUS; HISTOPATHOLOGY; IMMUNOPATHOGENESIS; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE; VIRUS MORPHOLOGY; VIRUS PATHOGENESIS;

ANIMAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, CYTOTOXIC; VIRAL PROTEINS;

EID: 0029148749     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/0270-9139(95)90645-2     Document Type: Article

References (61)

1. Immunobiology and pathogenesis of viral hepatitis
2. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan
3. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice
4. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state
5. Tissue preferential expression of the hepatitis B virus (HBV) surface antigen gene in two lines of HBV transgenic mice
6. Replication and gene expression of hepatitis B virus in a transgenic mouse that contains the complete viral genome
7. Expression and replication of hepatitis B virus genome in transgenic mice
8. HBx gene of hepatitis B virus induces liver cancer in transgenic mice
9. Tumor necrosis factor-alpha negatively regulates hepatitis B virus gene expression in transgenic mice
10. High-level hepatitis B virus replication in transgenic mice
11. Developmental regulation of hepatitis B surface antigen expression in two lines of hepatitis B virus transgenic mice
12. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice
13. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice
14. Hepadnavirus infection of peripheral blood lymphocytes in vivo: woodchuck and chimpanzee models of viral hepatitis
15. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice
16. Hepatitis B antigen: nature and distribution of cytoplasmic antigen in hepatocytes of carriers (37912)
17. Electron microscopy and immunoelectronmicroscopy of cytoplasmic hepatitis B antigen in hepatocytes
18. Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice
19. Expression of the hepatitis delta virus large and small antigens in transgenic mice
20. Hepatitis B surface antigen retention sensitizes the hepatocyte to injury by physiologic concentrations of gamma interferon
21. Overproduction of hepatitis B virus large envelope polypeptide causes filament storage, ground glass cell formation, hepatocellular injury and nodular hyperplasia in transgenic mice
22. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
23. Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice
24. Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice
25. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice
26. Mechanisms of class I restricted immunopathology: a transgenic mouse model of fulminant hepatitis
27. Class I restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo
28. CTL access to tissue antigen is restricted in vivo
29. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice
30. Interleukin 2 and interferon alpha/beta downregulate hepatitis B virus gene expression in vivo by tumor necrosis factor dependent and independent pathways
31. Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a post-transcriptional mechanism
32. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement
33. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?
34. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in HBV envelope transgenic mice
35. Extrathymic expression of the intracellular hepatitis B core antigen results in T cell tolerance in transgenic mice
36. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing “nonresponse” to HBsAg
37. Characterization of T-cell tolerance to hepatitis B virus (HBV) antigen in transgenic mice
38. Autoantibody production in hepatitis B e antigen transgenic mice elicited with a self T-cell peptide and inhibited with nonself peptides
39. Does maternal antibody to core antigen prevent recognition of transplacental transmission of hepatitis-B-virus infection
40. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity and associated with transcription factor ERCC3
41. High level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice
42. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice
43. Recognition efficiency of the hepatitis B virus polyadenylation signals is tissue specific in transgenic mice
44. A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/ NS1 protein: implication for an escape from antibody
45. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA
46. In vitro tumorigenicity of hepatitis B virus DNA and HBx protein
47. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice
48. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma
49. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth
50. Activation of multidrug resistance (P-glycoprotein) mdr3/mdrla gene during the development of hepatocellular carcinoma in hepatitis B virus transgenic mice
51. Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice
52. Instability of integrated hepatitis B virus DNA with inverted repeat structure in a transgenic mouse
53. Methylation of hepatitis B virus DNA and liver-specific suppression of RNA production in transgenic mouse
54. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model
55. Transfusion-associated non-A, non-B hepatitis: the first decade
56. Alcohol and cancer
57. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis
58. Hepatocellular carcinoma in type 1 glycogen storage disease
59. Chronic “cryptogenic” liver disease and malignant hepatoma in intermediate alpha-1-antitrypsin deficiency identified by a pi 2-specific monoclonal antibody
60. Risk of cirrhosis and primary liver cancer in alpha-1-antrypsin deficiency
61. Hepatocellular carcinoma in the non-cirrhotic liver: a comparison with that complicating cirrhosis